Skip to content
Triangle logo TriangleGet started
← Study library

NCT00483782 · CITED IN SOURCE DOCUMENTS

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2013-08-12

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and paclitaxel together with bevacizumab is more effective than carboplatin and paclitaxel alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer. PURPOSE: This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared with carboplatin and paclitaxel alone in treating patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer * Newly diagnosed disease * Meets 1 of the following staging criteria: * High-risk stage I or IIA disease (grade 3 disease or clear cell carcinoma only) * Stage IIB-IV disease (all grades and all histological types) * Must have undergone initial surgery (e.g., debulking cytoreductive surgery or a biopsy if the patient has stage IV disease) within the past 6 weeks * Patients with stage IV disease for which initial surgical debulking was not appropriate are eligible provided the following criteria are met: * Stage IV disease diagnosed by histology * No planned surgery prior to disease progression, including interval debulking surgery * Patients with prior early-stage ovarian epithelial or fallopian tube carcinoma treated with surgery alone are eligible at the time of diagnosis of abdominopelvic recurrence provided no further interval cytoreductive therapy is planned prior to disease progression * Synchronous primary endometrial carcinoma or a past history of primary endometrial carcinoma allowed provided the following criteria are met: * Disease ≤ stage IB * No more than superficial myometrial invasion * No lymphovascular invasion * Not poorly differentiated (i.e., no grade 3, papillary serous, or clear cell disease) * Measurable or nonmeasurable disease * No ovarian nonepithelial cancer, including malignant mixed Müllerian tumors * No borderline tumors (e.g., tumors of low malignant potential) * No history or clinical suspicion of brain metastases or spinal cord compression * CT scan or MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases * Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy \> 12 weeks * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL (can be post-transfusion) * INR ≤ 1.5 * APTT ≤ 1.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * ALT and AST ≤ 2.5 times ULN * Creatinine ≤ 2.0 mg/dL * Proteinuria ≤ 1+ by urine dipstick OR ≤ 1 g by 24-hour urine collection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 6 weeks after completion of study therapy * No significant traumatic injury within the past 4 weeks * No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months * No other malignancies within the past 5 years except for adequately treated carcinoma in situ of the cervix, and/or basal cell skin cancer, and/or early endometrial carcinoma * No pre-existing sensory or motor neuropathy ≥ grade 2 * No history or evidence of CNS disease (e.g., uncontrolled seizures) by neurological examination unless adequately treated with standard medical therapy * No history or evidence of thrombotic or hemorrhagic disorders * No uncontrolled hypertension (i.e., blood pressure \> 150/100 mm Hg despite antihypertensive therapy) * No known hypersensitivity to bevacizumab and its excipients, chemotherapy, or Cremophor EL * No nonhealing wound, ulcer, or bone fracture * Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require three weekly wound examinations * No clinically significant cardiovascular disease, including any of the following: * Myocardial infarction or unstable angina within the past 6 months * New York Heart Association class II-IV congestive heart failure * Poorly controlled cardiac arrhythmia despite medication * Rate-controlled atrial fibrillation allowed * Peripheral vascular disease ≥ grade 3 (i.e., symptomatic and interfering with activities of daily living requiring repair or revision) * No evidence of other disease or condition, metabolic dysfunction, physical examination findings, or laboratory findings that would contraindicate the use of an investigational drug or put the patient at high-risk for treatment-related complications PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 4 weeks since other prior surgery or open biopsy * No prior systemic therapy for ovarian cancer (e.g., chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy) * Prior adjuvant chemotherapy allowed for other malignancies (e.g., breast or colorectal carcinoma) if malignancy was diagnosed over 5 years ago with no evidence of subsequent recurrence * No prior mouse CA 125 antibody * No prior radiotherapy to the abdomen or pelvis * More than 10 days since prior and no concurrent chronic use of acetylsalicylic acid (\> 325 mg/day) * Low-dose (\< 325 mg/day) acetylsalicylic acid allowed * More than 10 days since prior and no concurrent full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes * Use of therapy for line patency allowed provided INR \< 1.5 * More than 30 days since prior and no other concurrent investigational agent or participation in another clinical trial * No other concurrent systemic antitumor agents * No concurrent surgery * No concurrent maintenance chemotherapy or intraperitoneal chemotherapy (including cytotoxic chemotherapy)
healthy Volunteers
false
minimum Age
18 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
interventions
  1. name
    bevacizumab
    type
    BIOLOGICAL
  2. name
    carboplatin
    type
    DRUG
  3. name
    paclitaxel
    type
    DRUG
  4. name
    questionnaire administration
    type
    OTHER
  5. name
    study of socioeconomic and demographic variables
    type
    OTHER
  6. name
    quality-of-life assessment
    type
    PROCEDURE
Study design
allocation
RANDOMIZED
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
1520
type
ESTIMATED
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Progression-free survival
secondary Outcomes
  1. measure
    Duration of overall survival
  2. measure
    Objective response rate
  3. measure
    Duration of response
  4. measure
    Biological progression-free interval as measured by increasing CA 125 levels
  5. measure
    Safety as measured by NCI CTAE version 3.0
  6. measure
    Quality of life
  7. measure
    Health economics
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and paclitaxel together with bevacizumab is more effective than carboplatin and paclitaxel alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer. PURPOSE: This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared with carboplatin and paclitaxel alone in treating patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
detailed Description
OBJECTIVES: Primary * Compare the progression-free survival and overall survival of patients with newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer treated with carboplatin and paclitaxel with vs without bevacizumab. Secondary * Compare the response rate in patients treated with these regimens. * Compare the duration of tumor response in patients treated with these regimens. * Compare the biological progression-free interval, as measured by increasing CA 125 levels, in patients treated with these regimens. * Compare the safety (e.g., adverse events, laboratory results, and performance status) of these regimens in these patients. * Compare the quality of life of patients treated with these regimens. * Compare the cost-effectiveness of these regimens in these patients. OUTLINE: This is a multicenter, open-label, randomized, controlled study. Patients are stratified according to FIGO stage (stage I-III with residual disease ≤ 1 cm vs stage I-III with residual disease \> 1 cm vs stage IV disease), intended time to start chemotherapy after surgery (≤ 4 weeks vs \> 4 weeks), and participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I (control): Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive bevacizumab IV over 30-90 minutes followed by paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab alone every 3 weeks for 12 courses. Quality of life is assessed at baseline, before every course, every 6 weeks for 1 year, every 3 months until disease progression or for up to 2 years, and then at 3 years. Health economic data is assessed periodically, including days of inpatient hospitalization visits, outpatient visits, and use of anticancer therapies. After completion of study treatment, patients are followed every 3-6 months for 5 years and then annually thereafter. Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Source references
references
  1. citation
    Dhillon S. Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Drugs. 2012 May 7;72(7):917-30. doi: 10.2165/11208940-000000000-00000.
    pmid
    22515620
    type
    BACKGROUND
  2. citation
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
    pmid
    22204725
    type
    RESULT
  3. citation
    Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
    pmid
    37185961
    type
    DERIVED
  4. citation
    Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.
    pmid
    21941283
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-0f1644822e735e215007
      requested nct id
      NCT00483782
      primary nct id
      NCT00483782
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
      payload sha256
      66e758c3927b96b96c14930111fb7615cb3f6cb2b3c2026ee1945b1cbb9e1b2d
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-0f1644822e735e215007
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00483782
      occurrences
      1. context exact
        </td> </tr> <tr> <td rowspan="2"> <strong> <a href="/clinicaltrials/NCT00483782">ICON7</a> </strong> [<a href="#cit/section_7.34">34</a>] </td> <td> <str
        end
        167483
        exact text
        NCT00483782
        start
        167472
      2. context exact
        /a>]</p> <p id="_760" tabindex="-1">Two phase III trials (<a href="/clinicaltrials/NCT00262847">GOG-0218</a> [NCT00262847] and <a href="/clinicaltrials/NCT00483782">ICON7 </a> [NCT00483782]) have evaluated the role of bevacizumab in first-line therapy for ovarian epithelial cancer, FTC, and PPC after surgical cytoreductio
        end
        184384
        exact text
        NCT00483782
        start
        184373
      3. context exact
        760" tabindex="-1">Two phase III trials (<a href="/clinicaltrials/NCT00262847">GOG-0218</a> [NCT00262847] and <a href="/clinicaltrials/NCT00483782">ICON7 </a> [NCT00483782]) have evaluated the role of bevacizumab in first-line therapy for ovarian epithelial cancer, FTC, and PPC after surgical cytoreduction.[<a href="#cit/section_
        end
        184409
        exact text
        NCT00483782
        start
        184398
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/ff9ceeeae0fbdc33fd.html
      source file sha256
      d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:10.059252+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      2a71979c192f62071168507c9e3b23e31a4e8fe2e21ca0f7ee294555ff0250c9
      source title
      Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025

    Preserved source evidence · Not medical advice